Core Insights - Hyperfine, Inc. (NASDAQ:HYPR) experienced a 15.6% decline in short interest in December, with total short interest at 659,270 shares as of December 15th, down from 780,752 shares on November 30th [2] - The stock opened at $0.98, with a market capitalization of $95.16 million, a fifty-day moving average of $1.06, and a two-hundred-day moving average of $1.14 [3] - The company reported an EPS of ($0.11) for the last quarter, missing the consensus estimate of ($0.10) by $0.01, with revenue of $3.44 million compared to the expected $3.51 million [4] Stock Performance - The stock has a fifty-two week low of $0.53 and a high of $2.22, with a price-to-earnings ratio of -1.88 and a beta of 1.09 [3] - The current days-to-cover ratio is 0.7 days based on an average daily volume of 894,142 shares [2] Analyst Ratings - Wall Street analysts have mixed ratings on Hyperfine, with two analysts rating it as a Buy, one as a Hold, and one as a Sell, resulting in a consensus rating of "Hold" and an average target price of $1.28 [6] Institutional Holdings - Institutional investors and hedge funds own 15.03% of Hyperfine's stock, with notable transactions including EP Wealth Advisors LLC acquiring a stake valued at approximately $25,000 and Vanguard Group Inc. increasing its position by 5.7% [7] Company Overview - Hyperfine, Inc. is a medical technology company focused on enhancing access to advanced neuroimaging through its portable MRI system, Swoop®, designed for bedside scanning in various clinical settings [8] - The Swoop system features a lightweight, wheeled design that allows for diagnostic imaging at the patient's bedside, minimizing the need for patient transport [9]